Quinlan M. Kile
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Quinlan M. Kile has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Jeffrey S. Miller
Department of Medicine, University of Minnesota, Minneapolis, USA
27 shared publications - Martin Felices
Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
27 shared publications - Philippa Kennedy
Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA
27 shared publications - Shee Kwan Phung
Masonic Cancer Center, University of Minnesota, Minneapolis, MN
27 shared publications - Melissa Khaw
Masonic Cancer Center, University of Minnesota, Minneapolis, MN
26 shared publications - Peter Hinderlie
Masonic Cancer Center, Minneapolis, Minnesota
26 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
Antigen specificity test of PSMA TriKE.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
Antigen specificity test of PSMA TriKE.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
PSMA TriKE testing against patient-derived xenograft (PDX).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
PSMA TriKE testing against patient-derived xenograft (PDX).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
MDSC phenotype and suppression.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
MDSC phenotype and suppression.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
Healthy donors and prostate cancer patient-derived NK cell killing capacity.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
Healthy donors and prostate cancer patient-derived NK cell killing capacity.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
Reagent list for time-of-flight mass cytometry (CyTOF).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
Reagent list for time-of-flight mass cytometry (CyTOF).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
PSMA abundance on C4-2 WT and C4-2 PSMA KO.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
PSMA abundance on C4-2 WT and C4-2 PSMA KO.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
Calculations of equifunctional dose of IL15 compared to PSMA TriKE.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
Calculations of equifunctional dose of IL15 compared to PSMA TriKE.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
Representative images (10X magnification) from the IncuCyte live cell imaging assay.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
Representative images (10X magnification) from the IncuCyte live cell imaging assay.